HealthTech firm Sanome has gained regulatory approval for its AI warning system which predicts healthcare-associated infections (HAIs) by analysing patient data from electronic patient records (EPRs).
MEMORI has been approved by the Medicines and Healthcare products Regulatory Agency and received EU Class IIb CE certification, paving the way for its rollout in the UK and Europe.
The AI medical device can identify HAIs up to 72 hours earlier than current methods by analysing live patient data, including vitals and clinical notes, from EPRs and delivering alerts into clinicians’ workflows.
Benedikt von Thüngen, founder and chief executive at Sanome, said: “My father died in hospital because early warning signs were missed.
“We didn’t set out to build just another AI tool, we set out to create something that means no one else has to experience what I did.
“MEMORI is about giving clinicians a window into the future, providing them insights and tools to act before it’s too late, and crucially, without creating additional burden.
“Achieving Class IIb certification is a major milestone in our journey and proves we can do that safely and at scale.”
HAIs, such as methicillin-resistant staphylococcus aureus (MRSA) and clostridium difficile (C. difficile), are estimated to cost the NHS around £2.7 billion a year and account for an additional seven million hospital bed days annually.
Sanome says that its AI tool aims to supports the NHS 10 year health plan by enabling earlier intervention, reducing complications and cost, and ultimately increasing hospital capacity.
The firm has also announced the appointment of three new members to its strategic advisory board: Lord James Bethell, former health minister and member of the House of Lords; Dr Arrash Yassaee, deputy director of MedTech Innovation at NHS England, and Professor Carole Longson, former chief scientific officer at the Association of the British Pharmaceutical Industry.
Lord Bethell said: “During my career, I’ve seen first-hand the pressure on our frontline services and how urgently we need smarter, faster tools to support clinical decisions and protect patients.
“What Sanome has built with MEMORI is more than just a breakthrough – it’s a transformative tool that allows clinicians to act sooner with more targeted interventions, saving lives, and reducing the pressures on an already burdened system.
“I’m proud to support a UK-grown solution that combines world-class science with a deep understanding of frontline healthcare.
“This is exactly the kind of innovation we need to build a more resilient, preventative NHS.”
Sanome is collaborating with NHS trusts and technology providers on data-sharing initiatives. It is also working towards achieving US Food and Drug Administration approval.
link